177 related articles for article (PubMed ID: 3354644)
1. Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk.
Haggitt RC; Reid BJ; Rabinovitch PS; Rubin CE
Am J Pathol; 1988 Apr; 131(1):53-61. PubMed ID: 3354644
[TBL] [Abstract][Full Text] [Related]
2. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1987 Jul; 93(1):1-11. PubMed ID: 3582897
[TBL] [Abstract][Full Text] [Related]
3. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.
Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757
[TBL] [Abstract][Full Text] [Related]
4. [Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases].
Robaszkiewicz M; Hardy E; Volant A; Nousbaum JB; Cauvin JM; Calament G; Robert FX; Saleun JP; Gouerou H
Gastroenterol Clin Biol; 1991; 15(10):703-10. PubMed ID: 1816011
[TBL] [Abstract][Full Text] [Related]
5. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
Reid BJ; Blount PL; Rubin CE; Levine DS; Haggitt RC; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1212-9. PubMed ID: 1551528
[TBL] [Abstract][Full Text] [Related]
6. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
7. Barrett's esophagus and esophageal adenocarcinoma.
Reid BJ
Gastroenterol Clin North Am; 1991 Dec; 20(4):817-34. PubMed ID: 1787015
[TBL] [Abstract][Full Text] [Related]
8. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
9. Mucin histochemistry in Barrett's esophagus.
Sirigu F; Capeccioni S; Dessì A
Riv Eur Sci Med Farmacol; 1990; 12(4-5):229-32. PubMed ID: 2103960
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
11. [Histologic occurrence of Barrett's carcinoma].
Naitoh H; Kodama M; Tani T; Kawaguchi A; Mekata E; Tamura H; Hosokawa M
Nihon Geka Gakkai Zasshi; 1999 Mar; 100(3):240-3. PubMed ID: 10379533
[TBL] [Abstract][Full Text] [Related]
12. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
[TBL] [Abstract][Full Text] [Related]
13. Barrett's esophagus and Barrett's-related dysplasia.
Goldblum JR
Mod Pathol; 2003 Apr; 16(4):316-24. PubMed ID: 12692197
[TBL] [Abstract][Full Text] [Related]
14. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.
Reid BJ; Levine DS; Longton G; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2000 Jul; 95(7):1669-76. PubMed ID: 10925966
[TBL] [Abstract][Full Text] [Related]
15. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus.
Fennerty MB; Sampliner RE; Way D; Riddell R; Steinbronn K; Garewal HS
Gastroenterology; 1989 Oct; 97(4):815-20. PubMed ID: 2777038
[TBL] [Abstract][Full Text] [Related]
16. DNA content in Barrett's esophagus and esophageal malignancy.
McKinley MJ; Budman DR; Grueneberg D; Bronzo RL; Weissman GS; Kahn E
Am J Gastroenterol; 1987 Oct; 82(10):1012-5. PubMed ID: 3661507
[TBL] [Abstract][Full Text] [Related]
17. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
18. [Histochemical diagnosis of short segment Barrett's esophagus].
Fujiyama Y; Ishizuka I; Koyama S
Nihon Rinsho; 2005 Aug; 63(8):1420-6. PubMed ID: 16101233
[TBL] [Abstract][Full Text] [Related]
19. Progression to cancer in Barrett's esophagus is associated with genomic instability.
Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
[TBL] [Abstract][Full Text] [Related]
20. Expression of sulfated carbohydrate chain and core peptides of mucin detected by monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma.
Endo T; Tamaki K; Arimura Y; Itoh F; Hinoda Y; Hareyama M; Irimura T; Fujita M; Imai K
J Gastroenterol; 1998 Dec; 33(6):811-5. PubMed ID: 9853552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
